Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 4

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 15Dermatologic 12Thoracic 8Other hematologic neoplasm 4Breast 4Head & Neck 2Sarcoma 1Plasma cell 1Myeloid 1Gastrointestinal 1Classical hematology 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 485Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 151Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Bexarotene × Breast × Clear all
NCT04664829 2025-09-23

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

National Cancer Centre, Singapore

Phase 1 Completed
12 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03323658 2023-01-10

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled 12 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT00003752 2013-05-30

Bexarotene in Treating Patients With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
180 enrolled
Breast

Breast Neoplasms

NCT00055991 2013-02-05

Bexarotene in Preventing Breast Cancer in Women at Genetic Risk

Baylor Breast Care Center

Phase 1 Completed
87 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡